抗血小板薬の世界市場-2025～2032年

抗血小板薬の世界市場は、2024年に27億581万米ドルに達し、2032年には50億5,603万米ドルに達すると予測され、予測期間2025～2032年のCAGRは8.2%で成長すると予測されます。

世界の抗血小板薬市場は、血小板凝集を阻害する薬剤に特化した製薬産業セグメントを包含し、血栓形成のリスクを低減します。これらの薬剤は、特に心血管疾患患者の心臓発作や脳卒中などの血栓性イベントの予防に不可欠です。

抗血小板薬は、血栓形成に重要な役割を果たす血液中の小さな細胞片である血小板の活性化や凝集を阻害します。血小板が凝集するのを防ぐことで、正常な血流を維持し、血栓形成に伴う合併症のリスクを低減します。抗血小板薬の一般的なクラスには、アデノシン二リン酸（ADP）受容体阻害薬とシクロオキシゲナーゼ阻害薬があります。

このクラスのアデノシン二リン酸（ADP）受容体阻害薬には、血小板上のADP受容体を遮断して活性化と凝集を防ぐクロピドグレルやチカグレロルなどの薬剤が含まれます。シクロオキシゲナーゼ阻害薬のアスピリンはよく知られた例で、血小板凝集の強力な促進因子であるトロンボキサンA2を産生する酵素を阻害します。これらの要因が、抗血小板薬の世界市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

心血管疾患の有病率の増加

心血管疾患（CVD）の有病率の増加は、世界の抗血小板薬市場の成長を大きく牽引しており、市場予測期間を通じて牽引していくと予想されます。

心血管疾患は世界の死亡の主要原因であり、2019年には全死亡の約32％を占め、同年の死亡者数は1,790万人でした。この憂慮すべき統計は、抗血小板療法を含む効果的な管理戦略の緊急の必要性を強調しています。CVDに罹患する人の増加に伴い、抗血小板薬を含む効果的な治療に対する需要も増加しています。

米国、欧州、アジアにおける心房細動（AF）の有病率の上昇は、世界の抗血小板薬市場を大きく押し上げると予想されます。National Center for Biotechnology Information（NCBI）によると、2020年6月に発表された調査によると、米国における心房細動患者数は2050年までに600万人から1,600万人に達する可能性があり、欧州やアジアでも同様の増加が予測されています。

アジアだけでも、2050年までに7,200万人が心房細動と診断されると予測されています。このような患者数の大幅な増加は、心房細動を管理することを目的とした治療の急成長市場を生み出すと予想されます。心房細動は脳卒中の主要な危険因子であり、アジアでは2050年までに約300万人が心房細動に関連した脳卒中を経験すると予測されています。このようなリスクの増加は、血栓塞栓イベントを予防する効果的な抗血小板療法の必要性を強調し、そのような薬剤の需要を促進します。これらすべての要因が、世界の抗血小板薬市場に需要をもたらしています。

これらの増加する心血管疾患（CVD）のために、業界の主要プレーヤーは臨床試験により多くの焦点を当て、肯定的な結果を得ることや、この抗血小板薬市場の成長を促進する重要な取り組みを行っています。例えば、2022年5月、PhaseBio Pharmaceuticalsは、ベントラシマブの米国食品医薬品局（FDA）とのバイオ医薬品承認申請（BLA）の前段階であるタイプBの事前会議（pre-BLA）を成功裏に完了したことを発表しました。この開発は、世界の抗血小板薬市場において重要な意味を持っています。

ベントラシマブは、チカグレロル（ブリリンタとして販売）の抗血小板作用を逆転させるために特別にデザインされた組換えヒトモノクローナル抗体フラグメントです。チカグレロルは経口P2Y12血小板阻害剤で、心血管系イベントのリスクがある患者の血栓予防に一般的に使用されています。チカグレロルは有効ではありますが、出血のリスクを高める可能性があり、特に緊急の外科的介入が必要な緊急時や出血がコントロールされていない症例では注意が必要です。ベントラシマブは、必要に応じて血小板機能を迅速に回復させることで、この問題に対処することを目指しています。

さらに、併用療法に対する需要の高まりが、世界の抗血小板薬市場の拡大に寄与しています。

薬剤に関連する副作用と禁忌

薬物に伴う副作用や禁忌は、抗血小板薬の世界市場の成長を抑制します。抗血小板薬の使用は心血管疾患の管理に不可欠ですが、いくつかの副作用や禁忌がその有効性と安全性を制限する可能性があります。これらの要因を理解することは、これらの薬剤を処方する際にヘルスケアプロバイダーにとって極めて重要です。

抗血小板薬には、上部消化管出血、悪心、下痢、出血性合併症、斑状出血、血尿、鼻出血、呼吸器への影響、チカグレロル関連呼吸困難、血小板減少症など、患者のアドヒアランスや安全性全般に影響を及ぼすさまざまな副作用があります。シロスタゾールに関連する一般的な副作用には、頭痛、動悸、不整脈、末梢浮腫などがあり、これらはすべて患者のQOLに悪影響を及ぼす可能性があります。

最近の脳卒中や出血、大手術、重篤な高血圧、末期腎不全や肝硬変、うっ血性心不全などの重篤な副作用のリスクが高まるため、抗血小板薬の使用を禁忌とする病状や状況があります。

抗血小板薬に関連する副作用と禁忌は、その処方に重大な課題をもたらします。ヘルスケアプロバイダーは、リスクを最小限に抑え、心血管疾患の効果的な管理を確実にするために、これらの薬剤を処方する前に、各患者の病歴と現在の健康状態を慎重に評価しなければなりません。治療戦略を最適化し、抗血小板療法を必要とする患者の転帰を改善するためには、これらの因子を認識することが重要です。したがって、上記の要因が世界の抗血小板薬市場の潜在的な成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 心血管疾患の罹患率の増加
  • 抑制要因
    • 薬剤に関連する副作用および禁忌
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 薬剤クラス別

• アデノシン二リン酸（ADP）受容体阻害剤
  • クロピドグレル
  • チカグレロル
  • プラスグレル
  • チクロピジン
  • カングレロール
• 不可逆的シクロオキシゲナーゼ（COX）阻害剤（アスピリン）
• 糖タンパク質IIb/IIIa阻害剤
  • アブシキシマブ
  • エプチフィバチド
  • チロフィバン
  • その他
• アデノシン再取り込み阻害剤（ジピリダモール）
• ホスホジエステラーゼ阻害剤（シロスタゾール）
• プロテアーゼ活性化受容体-1拮抗薬（ボラパキサール）
• トロンボキサン阻害剤（トリフルサール）

第7章 投与経路別

• 経口
• 非経口

第8章 用途別

• 心筋梗塞
• 経皮的冠動脈インターベンション（PCI）
• 動脈血栓症
• 脳卒中予防
• 末梢動脈疾患（PAD）
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第12章 企業プロファイル

• Sanofi
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• AstraZeneca.
• Eli Lilly and Company
• Chiesi USA, Inc.
• Healing Pharma India Pvt. Ltd.
• Taj Pharmaceuticals Limited.
• Merck & Co., Inc.
• Otsuka Pharmaceutical Company, Ltd.
• Boehringer Ingelheim International GmbH
• AdvaCare Pharma

第13章 付録

The global antiplatelet drugs market reached US$ 2,705.81 million in 2024 and is expected to reach US$ 5.056.03 million by 2032, growing at a CAGR of 8.2 % during the forecast period 2025-2032.

The global antiplatelet drugs market encompasses the pharmaceutical industry segment dedicated to medications that inhibit platelet aggregation, thereby reducing the risk of blood clot formation. These drugs are essential in preventing thrombotic events, such as heart attacks and strokes, particularly among patients with cardiovascular diseases.

Antiplatelet drugs interfere with the activation or aggregation of platelets, which are small cell fragments in the blood that play a crucial role in clot formation. By preventing platelets from clumping together, these medications help maintain normal blood flow and decrease the risk of complications associated with clotting. Common classes of antiplatelet drugs include adenosine diphosphate (ADP) receptor inhibitors and cyclooxygenase inhibitors.

Adenosine diphosphate (ADP) receptor inhibitors in this class include medications such as clopidogrel and ticagrelor, which block ADP receptors on platelets to prevent their activation and aggregation. Cyclooxygenase inhibitors aspirin is a well-known example that inhibits the enzyme responsible for producing thromboxane A2, a potent promoter of platelet aggregation. These factors have driven the global antiplatelet drugs market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Cardiovascular Diseases

The increasing prevalence of cardiovascular diseases(CVD) is significantly driving the growth of the global antiplatelet drugs market and is expected to drive throughout the market forecast period.

Cardiovascular diseases are the leading cause of mortality worldwide, accounting for approximately 32% of all deaths in 2019, with 17.9 million fatalities attributed to CVDs that year. This alarming statistic underscores the urgent need for effective management strategies, including antiplatelet therapy. As the number of individuals affected by CVD rises, the demand for effective treatments, including antiplatelet medications, correspondingly grows. Projected Increases in CVD Cases.

The rising prevalence of atrial fibrillation (AF) in the United States, Europe, and Asia is expected to significantly boost the global antiplatelet drugs market. According to the National Center for Biotechnology Information (NCBI), a research study published in June 2020 suggests that the number of individuals with AF in the U.S. could reach between 6 to 16 million by 2050, with similar increases anticipated in Europe and Asia.

In Asia alone, projections indicate that 72 million individuals will be diagnosed with AF by 2050. This substantial rise in the patient population will create a burgeoning market for treatments aimed at managing AF. AF is a major risk factor for stroke, with approximately 3 million individuals in Asia expected to experience AF-related strokes by 2050. This increased risk underscores the need for effective antiplatelet therapies to prevent thromboembolic events, driving demand for such medications. All these factors demand the global antiplatelet drugs market.

For these rising numbers of CVDs key players in the industry more focus on the clinical trials, getting positive results, and key initiatives that would prope this antiplatelet drug market growth. For instance, in May 2022, PhaseBio Pharmaceuticals announced the successful completion of a Type B pre-biologics license application (pre-BLA) meeting with the U.S. Food and Drug Administration (FDA) for bentracimab. This development is significant in the context of the global antiplatelet drugs market for several reasons.

Bentracimab is a recombinant human monoclonal antibody fragment specifically designed to reverse the antiplatelet effects of ticagrelor (marketed as Brilinta). Ticagrelor is an oral P2Y12 platelet inhibitor commonly used to prevent blood clots in patients at risk for cardiovascular events. While effective, ticagrelor can increase the risk of bleeding, particularly in emergencies that require urgent surgical intervention or in cases of uncontrolled bleeding. Bentracimab aims to address this issue by rapidly restoring platelet function when necessary.

Moreover, the rising demand for combination therapies contributes to the global antiplatelet drugs market expansion.

Adverse Effects and Contraindications Associated with the Medication

The adverse effects and contraindications associated with the medication will hinder the growth of the global antiplatelet drugs market. The use of antiplatelet drugs is vital in managing cardiovascular conditions, but several adverse effects and contraindications can limit their effectiveness and safety. Understanding these factors is crucial for healthcare providers when prescribing these medications.

Antiplatelet medications are associated with a variety of adverse effects that can impact patient adherence and overall safety issues such as upper gastrointestinal bleeding, nausea, diarrhea, bleeding complications, ecchymosis, hematuria, epistaxis, respiratory effects, ticagrelor-related dyspnea, thrombocytopenia. Common side effects associated with cilostazol include headache, palpitations, arrhythmias, and peripheral edema, all of which can negatively affect a patient's quality of life.

Certain medical conditions and circumstances contraindicate the use of antiplatelet drugs due to an increased risk of serious adverse effects such as Recent Stroke or hemorrhage, major surgery, severe hypertension, end-stage renal disease or decompensated liver cirrhosis, and congestive heart failure.

The adverse effects and contraindications associated with antiplatelet drugs present significant challenges in their use. Healthcare providers must carefully evaluate each patient's medical history and current health status before prescribing these medications to minimize risks and ensure effective management of cardiovascular conditions. Awareness of these factors is critical for optimizing treatment strategies and improving patient outcomes in those requiring antiplatelet therapy. Thus, the above factors could be limiting the global antiplatelet drugs market's potential growth.

For more details on this report - Request for Sample

Segment Analysis

The global antiplatelet drugs market is segmented based on drug class, route of administration, application, distribution channel, and region.

Drug Class:

The adenosine diphosphate (ADP) receptor inhibitors segment is expected to dominate the global antiplatelet drugs market share

The adenosine diphosphate (ADP) receptor inhibitors segment holds a major portion of the global antiplatelet drugs market share and is expected to continue holding a significant portion during the forecast period.

The global antiplatelet drugs market includes a variety of medications designed to inhibit platelet aggregation, thereby preventing thrombotic events, particularly in patients with cardiovascular diseases. A significant segment within this market is comprised of Adenosine Diphosphate (ADP) receptor inhibitors. Key drugs such as clopidogrel, ticagrelor, prasugrel, ticlopidine, and cangrelor.

ADP receptor inhibitors are a class of antiplatelet drugs that function by blocking the P2Y12 receptor on platelets. This blockade prevents the action of adenosine diphosphate (ADP), which is crucial for platelet activation and aggregation. By inhibiting this pathway, these medications significantly reduce the risk of thrombotic events such as heart attacks and strokes.

The demand for ADP receptor inhibitors will continue to rise due to their essential role in managing cardiovascular conditions. Healthcare providers are increasingly adopting combination therapies that incorporate these agents for enhanced efficacy, further propelling market growth.

Furthermore, key players in the industry have innovative product launches and approvals that would propel this segment's growth in the global antiplatelet drugs market. For instance, according to the BioMed Central Ltd research study in January 2024, Ticagrelor is a novel receptor antagonist that selectively binds to the P2Y12 receptor, effectively inhibiting adenosine diphosphate (ADP)-mediated platelet aggregation. Compared to clopidogrel, ticagrelor offers several advantages, including a rapid onset of action, potent effects, and reversible platelet inhibition.

These characteristics make ticagrelor particularly suitable for treating acute coronary syndrome (ACS), especially in cases of acute ST-segment elevation myocardial infarction (STEMI). As a promising option for the effective management of ACS, ticagrelor requires individualized treatment plans tailored to each patient's specific conditions to minimize the risk of serious adverse events.

Also, in February 2021, the European Union approved a new indication for Plavix (clopidogrel), a well-known antiplatelet medication. Plavix (clopidogrel) is an antiplatelet agent that functions by inhibiting the aggregation of platelets, which helps to decrease the risk of blood clot formation. These factors have solidified the segment's global antiplatelet drug market position.

Geographical Analysis

North America is expected to hold a significant position in the global antiplatelet drugs market share

North America holds a substantial position in the global antiplatelet drugs market and is expected to hold most of the market share.

The rising incidence of cardiovascular diseases, including myocardial infarction, stroke, coronary artery disease, and peripheral artery disease, is a major driver for the antiplatelet drugs market. In North America, cardiovascular diseases are among the leading causes of morbidity and mortality, necessitating effective antiplatelet therapies to reduce the risk of thrombotic events.

According to the Centers for Disease Control and Prevention (CDC), in the United States, heart disease remains the leading cause of death, with 702,880 deaths reported in 2022 equivalent to about 1 in every 5 deaths. Additionally, someone experiences a heart attack every 40 seconds, highlighting the critical need for preventive measures and treatments.

The aging population in North America is leading to an increased prevalence of age-related cardiovascular conditions. Older adults are more susceptible to heart diseases, driving the demand for antiplatelet medications as part of their treatment regimen. The demographic shift towards an older population is expected to continue, further increasing the need for effective cardiovascular treatments.

Continuous innovation and development of new antiplatelet agents with improved efficacy and safety profiles are expanding treatment options available to healthcare providers. The introduction of drugs like ticagrelor and prasugrel has enhanced patient outcomes and adherence rates, making these newer agents attractive options in clinical practice.

The North American market has witnessed a rise in regulatory approvals for new antiplatelet drugs and indications. For example, recent approvals for ticagrelor to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA) have broadened its use in clinical practice, thereby driving market growth. The North American market features a diverse array of antiplatelet medications, including aspirin, clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), and others. This variety allows healthcare providers to tailor treatments according to individual patient needs, further driving market growth.

Furthermore, key players in the industry product launches and approvals that would drive these antiplatelet drugs market growth. For instance, in December 2021, the U.S. Food and Drug Administration (FDA) approved two new indications for XARELTO (rivaroxaban), a medication designed to prevent and treat blood clots, specifically in pediatric patients. XARELTO is an oral anticoagulant that functions by inhibiting Factor Xa, a crucial element in the blood clotting cascade. Thus, the above factors are consolidating the region's position as a dominant force in the global antiplatelet drugs market.

Asia Pacific is growing at the fastest pace in the global antiplatelet drugs market share

Asia Pacific holds the fastest pace in the global antiplatelet drugs market and is expected to hold most of the market share.

The rising incidence of cardiovascular diseases (CVDs), including myocardial infarction, stroke, and peripheral artery disease, is a major driver for the antiplatelet drugs market in the APAC region. As lifestyles change and populations age, the demand for effective antiplatelet therapies to prevent thrombotic events continues to rise.

According to the World Health Organization (WHO), CVDs account for approximately 31% of all global deaths, highlighting the urgent need for effective treatment options. The global population living with heart and circulatory diseases is estimated at around 620 million, with projections indicating significant increases as populations age and lifestyle factors contribute to higher risk. For instance, it is estimated that by 2050, the number of individuals diagnosed with atrial fibrillation (AF) could reach between 6 to 16 million in the U.S. and 72 million in Asia.

The APAC region is witnessing a surge in clinical research activities focused on cardiovascular diseases and antiplatelet therapies. This research not only contributes to better treatment options but also enhances local expertise and innovation within the pharmaceutical industry. According to the National Center for Biotechnology Information (NCBI) research study in January 2025, DT-678 is an innovative antiplatelet prodrug designed to enhance the efficacy of clopidogrel, a widely used antiplatelet medication.

The unique mechanism of DT-678 allows it to release the active metabolite of clopidogrel (known as AM) upon exposure to glutathione, a naturally occurring antioxidant in the body. This study investigates the factors contributing to high on-treatment platelet reactivity (HTPR) observed in patients with acute coronary syndrome (ACS) and evaluates whether DT-678 can effectively overcome this issue.

The aging population in APAC countries, particularly in nations like Japan, China, and India, is contributing to a higher prevalence of age-related cardiovascular conditions. Older adults are more susceptible to heart diseases, which drives the demand for antiplatelet medications as part of their treatment regimen. This demographic shift is expected to increase the burden of CVD significantly over the coming years.

Continuous innovation and development of new antiplatelet agents with improved efficacy and safety profiles are expanding treatment options available to healthcare providers. The introduction of novel drugs and formulations enhances patient outcomes and adherence rates, making them more attractive options for clinicians. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global antiplatelet drugs market.

Competitive Landscape

The major global players in the antiplatelet drugs market include Sanofi, AstraZeneca., Eli Lilly and Company, Chiesi USA, Inc., Healing Pharma India Pvt. Ltd., Taj Pharmaceuticals Limited., Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Boehringer Ingelheim International GmbH, and AdvaCare Pharma among others.

Key Developments

• In August 2022, Bristol Myers Squibb, in collaboration with Janssen Pharmaceuticals, announced results from the Phase 2 AXIOMATIC-SSP dose-ranging study of milvexian, an investigational oral factor XIa (FXIa) inhibitor. This study demonstrated an approximate 30% relative risk reduction in recurrent symptomatic ischemic strokes when milvexian was used in combination with standard antiplatelet therapy compared to placebo. This finding is particularly relevant for patients who have experienced an acute non-cardioembolic ischemic stroke or transient ischemic attack (TIA).

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global antiplatelet drugs market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Route of Administration
• 3.3. Snippet by Application
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Cardiovascular Diseases
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects and Contraindications Associated with the Medication
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Adenosine Diphosphate (ADP) Receptor Inhibitors*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Clopidogrel
  • 6.2.4. Ticagrelor
  • 6.2.5. Prasugrel
  • 6.2.6. Ticlopidine
  • 6.2.7. Cangrelor
• 6.3. Irreversible Cyclooxygenase (COX) Inhibitors (Aspirin)
• 6.4. Glycoprotein IIb/IIIa Inhibitors
  • 6.4.1. Abciximab
  • 6.4.2. Eptifibatide
  • 6.4.3. Tirofiban
  • 6.4.4. Others
• 6.5. Adenosine Reuptake Inhibitors (Dipyridamole)
• 6.6. Phosphodiesterase Inhibitors (Cilostazol)
• 6.7. Protease-Activated Receptor-1 Antagonists (Vorapaxar)
• 6.8. Thromboxane Inhibitors (Triflusal)

7. By Route of Administration

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 7.1.2. Market Attractiveness Index, By Route of Administration
• 7.2. Oral *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Parenteral

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Myocardial Infarction*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Percutaneous Coronary Interventions (PCI)
• 8.4. Arterial Thrombosis
• 8.5. Stroke Prevention
• 8.6. Peripheral Artery Disease (PAD)
• 8.7. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Spain
    • 10.3.7.5. Italy
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. South Korea
    • 10.5.7.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Sanofi *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio
    • 12.1.2.1. Product Description
    • 12.1.2.2. Product Key Performance Indicators (KPIs)
    • 12.1.2.3. Historic and Forecasted Product Sales
    • 12.1.2.4. Product Sales Volume
  • 12.1.3. Financial Overview
    • 12.1.3.1. Company Revenue's
    • 12.1.3.2. Geographical Revenue Shares
    • 12.1.3.3. Revenue Forecasts
  • 12.1.4. Key Developments
    • 12.1.4.1. Mergers & Acquisitions
    • 12.1.4.2. Key Product Development Activities
    • 12.1.4.3. Regulatory Approvals etc.
  • 12.1.5. SWOT Analysis
• 12.2. AstraZeneca.
• 12.3. Eli Lilly and Company
• 12.4. Chiesi USA, Inc.
• 12.5. Healing Pharma India Pvt. Ltd.
• 12.6. Taj Pharmaceuticals Limited.
• 12.7. Merck & Co., Inc.
• 12.8. Otsuka Pharmaceutical Company, Ltd.
• 12.9. Boehringer Ingelheim International GmbH
• 12.10. AdvaCare Pharma

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us